UROGIN SAS IPS: public contracts won without a rival in Colombia: 3 uncontested awards; 60% of its awards; 3 without a competition; 0 single bid.
Assay record ASY-CO-1O3FE2A0G2 · Cite as: Assay Systems, “UROGIN SAS IPS: public contracts won without a rival in Colombia”, https://assay-systems.com/register/co/uncontested/s/urogin-sas-ips/
UROGIN SAS IPS won 3 of its 5 public contract awards in Colombia without a rival from 2026-01-01 to 2026-07-31: 3 without a competition and 0 after a competition that drew a single bid. 1 buyer awarded it without a rival, the largest E.S.E HOSPITAL UNIVERSITARIO SAN JORGE DE PEREIRA with 3.
An award is uncontested when the buyer had no rival offer to weigh: it was made without a competition (direct award, negotiated procedure without a call for tenders, sole-source or advance-notice contract), or a competition was held and only one bid arrived. Every count below is built award by award from the official notices. Awards to individuals are not included.
E.S.E HOSPITAL UNIVERSITARIO SAN JORGE DE PEREIRA gave UROGIN SAS IPS 3 awards: 3 without a competition, 0 after a competition with a single bid. First 2026-01-01, latest 2026-07-31.
| Date | Buyer | How | Stated reason |
|---|---|---|---|
| 2026-07-31 | E.S.E HOSPITAL UNIVERSITARIO SAN JORGE DE PEREIRA CO1.PCCNTR.9729992 | No competition Contratación régimen especial | Regla aplicable |
| 2026-04-21 | E.S.E HOSPITAL UNIVERSITARIO SAN JORGE DE PEREIRA CO1.PCCNTR.9464881 | No competition Contratación régimen especial | Regla aplicable |
| 2026-01-01 | E.S.E HOSPITAL UNIVERSITARIO SAN JORGE DE PEREIRA CO1.PCCNTR.8749344 | No competition Contratación régimen especial | Regla aplicable |
Every uncontested award in Colombia · All countries · UROGIN SAS IPS in the register
Source: SECOP II, Colombia Compra Eficiente open data (datos.gov.co). Awards are matched to their buyer and supplier as published. Values in these notices often state a framework ceiling rather than a contract amount, so awards are counted, not summed. Updated 17 October 2026.